TABLE 1.

Main patients' characteristics

	All n = 28
Gender
Male	21 (75%)
Female	7 (25%)
Median age (range)	29 (19–71)
Stage prior to anti‐PD1 therapy
I–II	6 (21%)
III–IV	22 (79%)
Extranodal disease prior to anti‐PD1 therapy	21 (75%)
B symptoms prior to anti‐PD1 therapy	10 (36%)
Bulky disease prior to anti‐PD1 therapy	6 (21%)
Response to anti PD‐1 therapy
Refractory	10 (36%)
Responsive	18 (64%)
Median number of anti PD‐1 cycles (range)	13 (3–72)
Median duration of anti PD‐1 therapy (mos)	6 (2–34)
Median number of prior therapies (range)	4 (2–11)
Prior BV	28 (100%)
Prior ASCT	18 (64%)
Prior RT	14 (50%)
Response to last chemotherapy prior to anti‐PD1 therapy
Refractory	26 (92%)
Responsive	2 (8%)